About the Company
bioatla is a protein therapeutic company that uses discovery and evolution to develop safer and more potent drugs for the treatment of cancer. the culmination of our discovery and evolution expertise and more than 150 issued patents and patent applications is our conditionally active biologics (cab) platform, whereby monoclonal antibodies or other biologics can be engineered for selective conditional activation, for example preferential binding under the unique conditions of the tumor microenvironment. this improvement in tumor selectivity helps address the issue of on-target toxicity and improve therapeutic index. bioatla is applying these technologies in our own pipeline and in partnerships to ultimately deliver better immunotherapies for cancer.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $BCAB News
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for ...
BioAtla Inc Ordinary Shares BCAB
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
BioAtla, Inc. (BCAB)
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB ...
BioAtla gets grant for patent granted for antibody binding to AXL protein
Discover how BioAtla's patented antibody targets Axl protein in cancer treatment. Learn about immunoconjugates, pharmaceutical compositions, and treatment methods covered in the US11897959B2 ...
Buy Rating Affirmed for BioAtla on Strong Clinical Pipeline and Financial Stability
JMP Securities analyst Reni Benjamin has reiterated their bullish stance on BCAB stock, giving a Buy rating on March 27. Reni Benjamin has ...
BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript
Greetings and welcome to the BioAtla Fourth Quarter and Full Year 2023 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the ...
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla, Inc. “We are excited to have several upcoming important milestones in the second quarter of this year including ...
PFIZER INC's Net Worth
PFIZER INC has an estimated net worth of $2.44 Billion. This is based on reported shares across multiple companies, which include BioAtla, Inc., Viatris Inc, Cerevel Therapeutics Holdings ...
BioAtla Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
BioAtla Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
BioAtla, Inc.: BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla, Inc. "We are excited to have several upcoming important milestones in the second quarter of this year including ...
BioAtla Inc.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Loading the latest forecasts...